Inflammation and bone marrow fibrosis: novel immunotherapeutic targets

Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management

(2023) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation

(2023) Wenjuan Fan et al.   ANNALS OF HEMATOLOGY

Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms

(2023) Raoul Tibes et al.   CANCER

Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1low model of myelofibrosis

(2023) Francesca Arciprete et al.   EXPERIMENTAL HEMATOLOGY

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

(2023) Srdan Verstovsek et al.   HAEMATOLOGICA

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model

(2023) Elisa Bianchi et al.   LEUKEMIA

Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis

(2023) Guadalupe Ferreira Gomes et al.   Current Hematologic Malignancy Reports

A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis

(2023) John Mascarenhas et al.   CLINICAL CANCER RESEARCH

Life histories of myeloproliferative neoplasms inferred from phylogenies

(2022) Nicholas Williams et al.   NATURE

CXCL4 drives fibrosis by promoting several key cellular and molecular processes

(2022) Alsya J. Affandi et al.   Cell Reports

HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression

(2022) Liping Li et al.   BLOOD

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes

(2022) John O. Mascarenhas et al.   CANCER

In utero origin of myelofibrosis presenting in adult monozygotic twins

(2022) Nikolaos Sousos et al.   NATURE MEDICINE

The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1low Mice

(2022) Paola Verachi et al.   Frontiers in Oncology

Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis

(2022) Lilian Varricchio et al.   Frontiers in Oncology

Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis

(2022) Harinder Gill   Cells

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis

(2022) Sara Stéphanie Lecomte et al.   BLOOD

IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms

(2022) Johanna Melo-Cardenas et al.   BLOOD

Anemia in myelofibrosis: current and emerging treatment options

(2022) Francesco Passamonti et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1 mouse model

(2022) Paola Verachi et al.   EXPERIMENTAL HEMATOLOGY

<i>ASXL1</i> mutations accelerate bone marrow fibrosis via EGR1-TNFA axis mediated neoplastic fibrocyte generation in myeloproliferative neoplasms

(2022) Zhongxun Shi et al.   HAEMATOLOGICA

The emerging importance of immunophilins in fibrosis development

(2022) Abdelrahim Alqudah et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm

(2022) Shivam Rai et al.   Nature Communications

Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm

(2022) Mohammed Ferdous-Ur Rahman et al.   Nature Communications

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression

(2022) Alessandro Malara et al.   Frontiers in Oncology

Biological drivers of clinical phenotype in myelofibrosis

(2022) John Mascarenhas et al.   LEUKEMIA

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms

(2021) Debra Van Egeren et al.   Cell Stem Cell

PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action

(2021) Miguel Hernandez-Quiles et al.   Frontiers in Endocrinology

Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021

(2021) Andrea Bacigalupo et al.   Frontiers in Immunology

Phase II study of single-agent nivolumab in patients with myelofibrosis

(2021) Iman Abou Dalle et al.   ANNALS OF HEMATOLOGY

Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms

(2021) Daniel Arthur Corpuz Fisher et al.   Frontiers in Immunology

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN

(2021) Stefan Tillmann et al.   Cancers

Cytokine Consistency Between Bone Marrow and Peripheral Blood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms

(2021) Pu Chen et al.   Frontiers in Medicine

The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation

(2021) Leandro Moretti et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition

(2021) Tim Kong et al.   Blood Advances

Crizanlizumab: First Approval

(2020) Hannah A. Blair   DRUGS

Sonic Hedgehog Signaling in Organogenesis, Tumors, and Tumor Microenvironments

(2020) Kuo-Shyang Jeng et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Adhesion to Fibronectin via α5β1 Integrin Supports Expansion of Megakaryocyte Lineage in Primary Myelofibrosis

(2020) Shinobu Matsuura et al.   BLOOD

Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets

(2020) Bethan Psaila et al.   MOLECULAR CELL

Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN

(2020) Helene Gleitz et al.   BLOOD

TGFβ-Directed Therapeutics: 2020

(2020) Beverly A. Teicher   PHARMACOLOGY & THERAPEUTICS

Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis

(2020) Nils B. Leimkühler et al.   Cell Stem Cell

IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis

(2020) Lucia Longhitano et al.   Aging-US

Luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) and primary myelofibrosis (PMF)

(2019) Pierre Fenaux et al.   BLOOD

Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling

(2019) Daniel A. C. Fisher et al.   LEUKEMIA

EDA fibronectin–TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis

(2019) Alessandro Malara et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib

(2019) Aaron T. Gerds et al.   LEUKEMIA RESEARCH

Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab

(2019) Takaaki Maekawa et al.   BLOOD

Neutral effect of Glioma-associated oncogene-1 expression on survival in myelofibrosis

(2019) Marko Lucijanic et al.   WIENER KLINISCHE WOCHENSCHRIFT

Fibronectin and its soluble EDA-FN isoform as biomarkers for inflammation and sepsis

(2019) Anna Lemańska-Perek et al.   Advances in Clinical and Experimental Medicine

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

(2019) Anders Lindholm Sørensen et al.   HAEMATOLOGICA

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms

(2018) Maria Kleppe et al.   CANCER CELL

Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion

(2018) William L. Heaton et al.   LEUKEMIA

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis

(2018) Margaux Sevin et al.   Nature Communications

Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target

(2018) Rebekka K. Schneider et al.   Cell Stem Cell

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients

(2017) S Ruberti et al.   LEUKEMIA

Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis

(2017) T Maekawa et al.   LEUKEMIA

Role of GARP in the activation of latent TGF-β1

(2017) Julie Stockis et al.   Molecular BioSystems

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies

(2016) A. A. Zahr et al.   HAEMATOLOGICA

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis

(2016) Srdan Verstovsek et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia

(2016) D A C Fisher et al.   LEUKEMIA

TGF-β: the master regulator of fibrosis

(2016) Xiao-ming Meng et al.   Nature Reviews Nephrology

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies

(2016) A. A. Zahr et al.   HAEMATOLOGICA

Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells

(2015) M. Lu et al.   BLOOD

MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF

(2015) E Bianchi et al.   CELL DEATH AND DIFFERENTIATION

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives

(2015) Hans Carl Hasselbalch et al.   MEDIATORS OF INFLAMMATION

P-Selectin Sustains Extramedullary Hematopoiesis in theGata1lowModel of Myelofibrosis

(2015) Gerald J. Spangrude et al.   STEM CELLS

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

(2014) Neha Bhagwat et al.   BLOOD

Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms

(2014) D. Niebel et al.   BLOOD

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis

(2014) R. Norfo et al.   BLOOD

Cell Stress Induces Upregulation of Osteopontin via the ERK Pathway in Type II Alveolar Epithelial Cells

(2014) Aki Kato et al.   PLoS One

The role of cytokines in the initiation and progression of myelofibrosis

(2013) Hans C. Hasselbalch   CYTOKINE & GROWTH FACTOR REVIEWS

The complexity of NF-κB signaling in inflammation and cancer

(2013) Bastian Hoesel et al.   Molecular Cancer

PPARγ is an E3 ligase that induces the degradation of NFκB/p65

(2012) Yongzhong Hou et al.   Nature Communications

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum Amyloid P Inhibits Fibrosis Through Fc R-Dependent Monocyte-Macrophage Regulation in Vivo

(2009) A. P. Castano et al.   Science Translational Medicine